Aurinia Pharmaceuticals Inc. (AUPH) · Aug 19, 2026 · Material agreement
Patent settlement — Settlement terms, payment details, and generic launch date not disclosed
Aurinia resolves Teva’s voclosporin patent litigation, removing courtroom uncertainty—but the filing reveals no launch date or settlement economics.
The legal overhang is resolved, but the financial read is incomplete. Aurinia and Teva entered a settlement covering Teva’s proposed generic 7.9 mg voclosporin capsules. 〔0〕 (8-K narrative)
This is not yet a clean win versus expectations. The filing confirms the dispute is settled, but provides no agreed generic launch date, payment to Aurinia, royalty, supply arrangement, or other economic term. Without those details, the market cannot determine from this filing whether Teva is delayed until patent expiry or gains an earlier commercial entry.
| Item | Filing disclosure |
|---|---|
| Counterparty | Teva Pharmaceuticals Inc. (8-K narrative) |
| Product affected | Generic 7.9 mg voclosporin oral capsules (8-K narrative) |
| Purpose | Resolve patent infringement litigation (8-K narrative) |
| Settlement economics | Not disclosed |
| Generic launch timing | Not disclosed |
The immediate change is lower litigation uncertainty, not a quantified upgrade to LUPKYNIS economics. The settlement removes the binary risk of a court outcome, but the absent commercial terms leave the most important investor question—when generic competition can begin—unanswered. Relative to the standing expectation, this is best classified as a new but incomplete event rather than a substantiated beat or miss.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!